Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 19:2022:7677252.
doi: 10.1155/2022/7677252. eCollection 2022.

Association of AGTR1 A1166C and CYP2C9∗3 Gene Polymorphisms with the Antihypertensive Effect of Valsartan

Yi Liu  1 , Xiaomu Kong  1 , Yongwei Jiang  1 , Meimei Zhao  1 , Peng Gao  1 , Xiao Cong  1 , Yongtong Cao  1 , Liang Ma  1
Affiliations

Association of AGTR1 A1166C and CYP2C9∗3 Gene Polymorphisms with the Antihypertensive Effect of Valsartan

Yi Liu et al. Int J Hypertens. .

Abstract

Background: The differences in the antihypertensive treatment with angiotensin type II receptor blockers (ARBs) may be attributed to polymorphisms in genes involving drug-targeted receptor and drug metabolism. The present study aimed to investigate whether the antihypertensive effect of the ARB drug valsartan was associated with angiotensin II type 1 receptor (AGTR1) gene polymorphism (A1166 C) and cytochrome P450 enzyme 2C9 (CYP2C9) gene polymorphism (CYP2C9∗3).

Methods: 281 patients with hypertension who received valsartan monotherapy in the past month were included in this retrospective study. Polymerase chain reaction-melting curve analysis was performed to genotype the AGTR1 and CYP2C9 gene polymorphisms. Based on the systolic blood pressure (SBP) and diastolic blood pressure (DBP) at the time of visit, the patients were divided into well-controlled group (n = 144, SBP/DBP <140/90 mmHg) and poorly controlled group (n = 137, SBP/DBP ≥140/90 mmHg).

Results: Older age, decreased history of drinking, a higher proportion of mild-to-moderate hypertension, lower alanine aminotransferase levels, and higher high-density lipoprotein cholesterol levels were observed in the well-controlled group than the poorly controlled group. Higher frequencies of the C allele and AC + CC genotype of AGTR1 A1166C were detected in the well-controlled than the poorly controlled patients (P = 0.005 and P = 0.006). After adjustment for demographic and environmental factors, the CC + AC genotype of AGTR1 A1166C was markedly linked to better hypertension control with valsartan treatment compared to the AA genotype (odds ratio: 2.836, 95% confidence interval: 1.199-6.705, P = 0.018). No significant difference was observed in the allele or genotype distribution of CYP2C9∗3 polymorphism between well-controlled and poorly controlled patients.

Conclusions: The current data suggested that the AGTR1 A1166 C polymorphism may be associated with the antihypertensive effect of valsartan, and carriers with AC and CC genotypes may have a better antihypertensive efficacy response to valsartan treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Figures

Figure 1
Figure 1
Study population flowchart.
See this image and copyright information in PMC

References

    1. Lawes C. M., Vander Hoorn S., Rodgers A. International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet . 2008;371(9623):1513–1518. doi: 10.1016/S0140-6736(08)60655-8. - DOI - PubMed
    1. World Health Organization. A Global Brief on Hypertension: Silent Killer, Global Public Health Crisis: World Health Day 2013 . Geneva, Switzerland: World Health Organization; 2013. https://www.who.int/cardiovascular_diseases/publications/global_brief_hy...
    1. GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet . 2018;392(10159):1923–1994. doi: 10.1016/S0140-6736(18)32225-6. - DOI - PMC - PubMed
    1. Joint Committee for Guideline Revision. 2018 Chinese guidelines for prevention and treatment of hypertension-a report of the revision committee of Chinese guidelines for prevention and treatment of hypertension. Journal of Geriatric Cardiology . 2019;16(3):182–241. doi: 10.11909/j.issn.1671-5411.2019.03.014. - DOI - PMC - PubMed
    1. Wang Z., Chen Z., Zhang L., et al. Status of hypertension in China: results from the China hypertension survey, 2012-2015. Circulation . 2018;137(22):2344–2356. doi: 10.1161/circulationaha.117.032380. - DOI - PubMed

LinkOut - more resources